CNBX Pharmaceuticals Inc. (CNBX): Operating Cash Flow
-$171.3K
Year ended 2025-08-31
-$154.2K
Trailing 12 months to 2026-05-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-08-31 | -$171.3K | n/m | 2025-12-01, From 2024-09-01 |
| 2024-08-31 | -$244.3K | n/m | 2025-12-01, From 2023-09-01 |
| 2023-08-31 | -$112.5K | n/m | 2024-11-29, From 2022-09-01 |
| 2022-08-31 | -$1.68M | n/m | 2023-11-30, From 2021-09-01 |
| 2021-08-31 | -$2.49M | n/m | 2022-11-30, From 2020-09-01 |
| 2020-08-31 | -$2.77M | n/m | 2021-11-29, From 2019-09-01 |
| 2019-08-31 | -$3.09M | n/m | 2020-11-04, From 2018-09-01 |
| 2018-08-31 | -$1.97M | n/m | 2019-11-29, From 2017-09-01 |
| 2017-08-31 | -$863.6K | n/m | 2018-11-29, From 2016-09-01 |
| 2016-08-31 | -$120.1K | n/m | 2017-12-08, From 2015-09-01 |
| 2015-08-31 | -$179.1K | n/m | 2016-12-13, From 2014-09-01 |
| 2014-08-31 | -$195.4K | n/m | 2016-01-07, From 2013-09-01 |
| 2013-08-31 | -$27.2K | n/a | 2013-11-29, From 2012-09-01 |
| No annual figure between 2010-08-31 and 2013-08-31. | |||
| 2010-08-31 | $6.0K | n/a | 2011-11-29, From 2009-09-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| CNBX Pharmaceuticals Inc. (CNBX) | 2025-08-31 | -$171.3K | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $2.45M | +109.7% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
Compare CNBX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗